Suchergebnisse - "Samuel, Rafik"

PubPharm (43)

1

HIV : how to manage heavily treatment-experienced patients

enthalten in: Drugs in context | 2022

von Spivack, S. | Pagkalinawan, S. | Samuel, R. | +1

2

Perceptions of Long-Acting Injectable Antiretroviral Treatment Regimens in a United States Urban Academic Medical Center

enthalten in: Journal of the International Association of Providers of AIDS Care | 2020

von Koren, D. | Fedkiv, V. | Zhao, H. | +4

3

Impact of an Antiretroviral Stewardship Team on the Care of Patients With Human Immunodeficiency Virus Infection Admitted to an Academic Medical Center

enthalten in: Open forum infectious diseases | 2019

von DePuy, A. | Samuel, R. | Mohrien, K. | +2

4

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA) : week 48 results from a randomised, open-label, non-inferiority, phase 3b study

enthalten in: The lancet. HIV | 2017

von Orrell, C. | Hagins, D. | Belonosova, E. | +104

CommentIn: Lancet HIV. 2017 Dec;4(12 ):e530-e531. - PMID 28729157

5

Antibiotics manual : a guide to commonly used antimicrobials

Erschienen: Hoboken, NJ, John Wiley & Sons Ltd, 2017

Second edition

von Schlossberg, D. | Samuel, R.

6

Antibiotics manual : a guide to commonly used antimicrobials

Erschienen: Hoboken, NJ, Wiley Blackwell, 2017

Second edition

von Schlossberg, D. | Samuel, R.

7

Antibiotics : A Guide to Commonly Used Antimicrobials

Erschienen: Newark, John Wiley & Sons, Incorporated, 2017

2nd ed

von Schlossberg, D. | Samuel, R.

8

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions : 48-week results from VIKING-4, a randomized study

enthalten in: Antiviral therapy | 2015

von Akil, B. | Blick, G. | Hagins, D. | +24

9

Mapping patient-identified barriers and facilitators to retention in HIV care and antiretroviral therapy adherence to Andersen's Behavioral Model

enthalten in: AIDS care | 2015

von Holtzman, C. | Shea, J. | Glanz, K. | +7

10

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study

enthalten in: Antiviral therapy | 2014

von Akil, B. | Blick, G. | Hagins, D. | +8

1
2
3
4
5
Nächster »
[5]